BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt

Reuters

Feb 09

Feb 9 (Reuters) - Biofrontera Inc BFRI.O:

BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ® PDT FOR ACTINIC KERATOSES ON THE EXTREMITIES, NECK, AND TRUNK, MEETING PRIMARY ENDPOINT
BIOFRONTERA INC - PRIMARY ENDPOINT ACHIEVED WITH COMPLETE CLEARANCE RATE OF AK LESIONS
BIOFRONTERA INC - AMELUZ PDT ACHIEVES 45.6% CLEARANCE RATE IN PHASE 3 STUDY
BIOFRONTERA INC - AK LESION CLEARANCE 73.1% IN FAS AND 80.3% IN PPS
BIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026

Source text: ID:nGNX7gV97j

Further company coverage: BFRI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610065916"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610065916\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610065916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610065916","market":"us","top_or_hot":-1,"title":"BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt </title></head><body><p><span>Feb 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a> <span>BFRI.O</span>:</p><ul><li><p>BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ® PDT FOR ACTINIC KERATOSES ON THE EXTREMITIES, NECK, AND TRUNK, MEETING PRIMARY ENDPOINT</p></li><li><p>BIOFRONTERA INC - PRIMARY ENDPOINT ACHIEVED WITH COMPLETE CLEARANCE RATE OF AK LESIONS</p></li><li><p>BIOFRONTERA INC - AMELUZ PDT ACHIEVES 45.6% CLEARANCE RATE IN PHASE 3 STUDY</p></li><li><p>BIOFRONTERA INC - AK LESION CLEARANCE 73.1% IN FAS AND 80.3% IN PPS</p></li><li><p>BIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026</p></li></ul><p>Source text: <span>ID:nGNX7gV97j</span></p><p>Further company coverage: <span>BFRI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-09 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt </title></head><body><p><span>Feb 9 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a> <span>BFRI.O</span>:</p><ul><li><p>BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ® PDT FOR ACTINIC KERATOSES ON THE EXTREMITIES, NECK, AND TRUNK, MEETING PRIMARY ENDPOINT</p></li><li><p>BIOFRONTERA INC - PRIMARY ENDPOINT ACHIEVED WITH COMPLETE CLEARANCE RATE OF AK LESIONS</p></li><li><p>BIOFRONTERA INC - AMELUZ PDT ACHIEVES 45.6% CLEARANCE RATE IN PHASE 3 STUDY</p></li><li><p>BIOFRONTERA INC - AK LESION CLEARANCE 73.1% IN FAS AND 80.3% IN PPS</p></li><li><p>BIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026</p></li></ul><p>Source text: <span>ID:nGNX7gV97j</span></p><p>Further company coverage: <span>BFRI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BFRIW","symbol_name":"Biofrontera Inc Warrant","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:1","article_id":"2610065916","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610065916","pubTimestamp":1770648094,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz Pdt Feb 9 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ PDT FOR ACTINIC K","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BFRIW":"Biofrontera Inc Warrant","BFRI":"Biofrontera Inc","BK4007":"制药"},"translate_title":"简介-Biofrontera宣布Ameluz 3期研究取得积极结果®Pdt","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFRIW":0.9,"BFRI":0.9},"content_text":"BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt Feb 9 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ® PDT FOR ACTINIC KERATOSES ON THE EXTREMITIES, NECK, AND TRUNK, MEETING PRIMARY ENDPOINTBIOFRONTERA INC - PRIMARY ENDPOINT ACHIEVED WITH COMPLETE CLEARANCE RATE OF AK LESIONSBIOFRONTERA INC - AMELUZ PDT ACHIEVES 45.6% CLEARANCE RATE IN PHASE 3 STUDYBIOFRONTERA INC - AK LESION CLEARANCE 73.1% IN FAS AND 80.3% IN PPSBIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026Source text: ID:nGNX7gV97jFurther company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}